LENSAR, Inc. (LNSR)
| Market Cap | 101.97M -29.9% |
| Revenue (ttm) | 60.26M +3.3% |
| Net Income | 14.70M |
| EPS | 0.53 |
| Shares Out | 12.29M |
| PE Ratio | 15.64 |
| Forward PE | 4.82 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 142,321 |
| Open | 8.52 |
| Previous Close | 8.46 |
| Day's Range | 8.23 - 8.52 |
| 52-Week Range | 4.95 - 12.94 |
| Beta | 0.88 |
| Analysts | Strong Buy |
| Price Target | 11.50 (+38.55%) |
| Earnings Date | Aug 13, 2026 |
About LNSR
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally. The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision. It also provides ALLY Robotic... [Read more]
Financial Performance
In 2025, LENSAR's revenue was $58.44 million, an increase of 9.24% compared to the previous year's $53.49 million. Losses were -$34.28 million, 9.16% more than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for LNSR stock is "Strong Buy." The 12-month stock price target is $11.5, which is an increase of 38.55% from the latest price.
News
Lensar price target raised to $10 from $9 at BTIG
BTIG analyst Ryan Zimmerman raised the firm’s price target on Lensar (LNSR) to $10 from $9 and keeps a Buy rating on the shares as part of a broader research…
Lensar price target raised to $13 from $10 at Lake Street
Lake Street analyst Frank Takkinen raised the firm’s price target on Lensar (LNSR) to $13 from $10 and keeps a Buy rating on the shares. The firm, which thinks Lensar…
Lensar management to meet virtually with Lake Street
Virtual Meeting to be held on August 20 hosted by Lake Street.
LENSAR Earnings Call Transcript: Q2 2026
Q2 2026 saw 18% revenue growth, record adjusted EBITDA, and a 20% rise in recurring revenue, with ALLY system adoption driving market share gains and profitability. Gross margin improved to 59% (52% excluding a tariff refund), and the installed base expanded globally.
LENSAR Earnings release: Q2 2026
LENSAR released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
LENSAR Quarterly report: Q2 2026
LENSAR has published its Q2 2026 quarterly earnings report on August 13, 2026.
LENSAR® Reports Second Quarter 2026 Results and Provides Business Update
10 ALLY Robotic Cataract Laser Systems® (“ALLY System”) Placements in Second Quarter 2026; Backlog of 13 ALLY Systems as of June 30, 2026 Second Quarter Recurring Revenue was $13.7 million Total Laser...
LENSAR Transcript: AGM 2026
The meeting covered board elections, auditor ratification, and executive compensation votes. All proposals passed, with directors re-elected, auditor confirmed, and annual advisory votes on compensation approved. No questions were raised by stockholders.
LENSAR Proxy statement: Proxy filing
LENSAR filed a proxy statement on June 23, 2026, providing details for shareholder voting and corporate governance matters.
LENSAR Proxy statement: Proxy filing
LENSAR filed a proxy statement on June 23, 2026, providing details for shareholder voting and corporate governance matters.
LENSAR Earnings Call Transcript: Q1 2026
Revenue declined 5% year-over-year due to lower system sales, but recurring revenue grew 9% and now represents 94% of total revenue. The company is rebuilding momentum post-merger termination, with international placements resuming and strong recurring revenue expected to drive future growth.
LENSAR Earnings release: Q1 2026
LENSAR released its Q1 2026 earnings on May 8, 2026, summarizing the period's financial results.
LENSAR Quarterly report: Q1 2026
LENSAR has published its Q1 2026 quarterly earnings report on May 8, 2026.
LENSAR® Reports First Quarter 2026 Results and Provides Business Update
7 ALLY Robotic Cataract Laser Systems® (“ALLY System”) Placements in First Quarter 2026; Backlog of 11 ALLY Systems as of March 31, 2026
LENSAR Slides: Corporate presentation
LENSAR has posted slides in relation to its latest quarterly earnings report, which was published on May 8, 2026.
LENSAR® to Report First Quarter 2026 Results on May 8, 2026
ORLANDO, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treat...
Lensar upgraded to Buy from Hold at Lake Street
Lake Street upgraded Lensar (LNSR) to Buy from Hold with a price target of $10, down from $15. Lensar’s ALLY is “without a doubt the best femtosecond laser on the…
LENSAR Earnings Call Transcript: Q4 2025
2025 saw strong recurring revenue and procedure growth despite acquisition-related disruptions, with LENSAR regaining independence and focusing on expanding its installed base and international reach. Gross margins remained healthy, and positive adjusted EBITDA was achieved.
LENSAR Annual report: Q4 2025
LENSAR has published its Q4 2025 annual report on March 31, 2026.
LENSAR Earnings release: Q4 2025
LENSAR released its Q4 2025 earnings on March 31, 2026, summarizing the period's financial results.
Lensar reports Q4 EPS (12c) vs. ($1.61) last year
Reports Q4 revenue $16.03M vs. $16.73M last year. “While the recent transaction-related news was unexpected, we have quickly pivoted and are moving forward independently with a renewed commitment to a...
LENSAR® Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update
15 ALLY Robotic Cataract Laser Systems® (“ALLY Systems”) placed in 4Q 2025; Backlog of 13 ALLY Systems pending installation as of December 31, 2025
Lensar upgraded to Buy from Neutral at BTIG
BTIG upgraded Lensar (LNSR) to Buy from Neutral with a $10 price target. Prior to the Alcon (ALC) acquisition announcement in March of last year, Lensar was seeing strong growing…
Lensar down 23% following termination of merger agreement with Alcon
17:01 EDT Lensar (LNSR) down 23% following termination of merger agreement with Alcon (ALC)